Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

PF-03550096

Selective full CB2 agonist (human Ki 7.9 nM), orally active in a rat model of visceral hypersensitivity.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₁₉H₂₈N₄O₄

CAS 910376-39-5

Family
Synthetic CB receptor agonistResearch ligand or medicine
Molar mass
376.40 g/mol

Updated on

In plain terms

PF-03550096 is a laboratory molecule that activates the CB2 receptor, found mostly outside the brain, notably in the immune system and the gut. In rats, it inhibited the lowering of the colonic pain threshold induced by an inflammatory agent. No use in humans was found.

Receptors and activity

Target network

CB2AgonistKi = 7.9 nM · humanhuman CB2 (7.9 ± 1.7 nM); rat CB2 47 ± 5.6 nM; full agonist in a cell assay (Kikuchi et al. 2008)
  • Activates
  • Binds or modulates

The lower the cited value, the closer the target sits to PF-03550096: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PF-03550096.

Brain, side view
Body, front view
Blood

CB2CB2 found in 5 regions of the body

  1. SpleendenseHighly abundant in the spleen1
  2. Immune cellspresentMainly B cells and natural killer cells1
  3. SkinpresentKeratinocytes, mast cells and nerve fibres2
  4. GutpresentImmune cells of the colonic mucosa3
  5. BonepresentPresent on osteoclasts4

Cited values

  1. CB2AgonistKi = 7.9 nM · human68 out of 100

    Kikuchi et al., J Pharmacol Sci 2008: pharmacological evaluation of PF-03550096, a CB2 ligand, in vitro and in a rat model of visceral hypersensitivity (new tab) · human CB2 (7.9 ± 1.7 nM); rat CB2 47 ± 5.6 nM; full agonist in a cell assay (Kikuchi et al. 2008)

  2. CB1Binding (function not established)Ki = 1.5 µM · human31 out of 100

    Omura et al., Bioorg Med Chem Lett 2008: structure-activity studies of benzimidazolone derivatives, novel selective CB2 agonists (values read in ChEMBL, document CHEMBL1150312) (new tab) · [3H]SR141716A displacement at human CB1 (value read in ChEMBL, Omura et al. 2008)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

PF-03550096 belongs to a strategy of cannabinoid pharmacology applied to pain: targeting the CB2 receptor rather than CB1. Kikuchi and colleagues describe in 2008 a compound of this class, built on a benzimidazolone core remote from the usual cannabinoid chemotypes. The measured affinity is high at the human CB2 receptor (Ki of 7.9 nM) and lower at the rat one (47 nM), and the compound behaves as a full agonist in a cell assay. The values read in ChEMBL for the structure-activity study of Omura et al. (2008) give a Ki of 1,459 nM at human CB1. Given orally to rats, it inhibited the TNBS-induced lowering of colonic pain threshold, an effect reversed by SR144528 (Kikuchi et al. 2008). No clinical study and no pharmacokinetic or safety data in humans were found in the sources consulted.

History

Source
Entirely synthetic compound with no known natural occurrence. It was produced in a Pfizer pharmaceutical research programme; no clinical development or marketing was found in the sources consulted.

Origin

Laboratory synthesis

No known biosynthetic pathway: a synthetic molecule. It is a benzimidazol-2-one carboxamide, N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-3-(3-hydroxy-3-methylbutyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide (name from the title of Kikuchi et al. 2008).

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › Research ligand or medicine

Class

benzimidazolone-carboxamide

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

PF-03550096 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(3-hydroxy-3-methylbutyl)-2-oxobenzimidazole-1-carboxamide
Other names
PF 03550096 · PF-3550096

Identifiers

Formula
C₁₉H₂₈N₄O₄
CAS
910376-39-5
InChIKey
GGNIFXBIJCNXCT-CQSZACIVSA-N
SMILES
CC(C)(C)[C@@H](C(=O)N)NC(=O)N1C2=CC=CC=C2N(C1=O)CCC(C)(C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.